Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity
12 September 2023 - 9:30PM
Syneos Health® (Nasdaq:SYNH), a leading fully integrated
biopharmaceutical solutions organization, today announced a
strategic collaboration that will expand its relationship with
Oracle. Using the Oracle Cerner Learning Health Network (LHN) and
elements of Oracle’s suite of study startup solutions, the
companies seek to help reduce the time it takes to recruit patients
for clinical studies and increase the diversity of patient
populations participating in medical research.
Syneos Health is evolving its patient recruitment capabilities
to further address unmet sponsor, site and patient needs. Through
its collaboration with the Oracle Cerner LHN, Syneos Health’s
objective is to improve performance throughout the entire clinical
trial lifecycle, with a strong emphasis on clinical trial
enrollment to help close diversity gaps in patient recruitment.
“At Syneos Health, we are committed to closing the gaps that
exist in clinical trial recruitment – from helping identify the
right patients for a study to ensuring a diverse patient
population,” said Baba Shetty, President, Technology & Data
Solutions, Syneos Health. “Collaborating with Oracle will
demonstrate our goal of continued investment in technology and data
solutions that accelerate clinical development and optimize
performance for our customers.”
The Oracle Cerner LHN is a nationwide network of diverse health
systems ranging from small clinics to large hospitals that share
de-identified, real-world data to help physicians advance clinical
research. Oracle’s site selection capabilities, the Oracle Cerner
LHN and Syneos Health’s clinical recruitment capabilities aim to
provide physicians with greater access to a diverse set of data to
bring clinical trial opportunities to a broader group of patients
and speed new therapies to market.
“Current clinical research recruitment is a lengthy and complex
process that makes it difficult to reach diverse populations and
deliver much-needed treatments to market in a timely manner,” said
Seema Verma, Senior Vice President and General Manager, Oracle Life
Sciences. “Access to this vast real-world health data can
dramatically change recruitment practices and increase inclusion
and diversity in clinical trials. Working in tandem with Syneos
Health, we hope to help our customers conduct more efficient trials
and outcomes-based research.”
Learn more about Syneos Health and Oracle’s collaboration at the
Oracle Health Conference Sept. 18-20, 2023 in Las Vegas. For more
information visit:
https://www.oracle.com/oracle-health-conference/.
TrademarksOracle, Java, MySQL and NetSuite are
registered trademarks of Oracle Corporation. NetSuite was the first
cloud company--ushering in the new era of cloud computing.
About Syneos HealthSyneos Health® (Nasdaq:SYNH)
is a leading fully integrated biopharmaceutical solutions
organization built to accelerate customer success. We translate
unique clinical, medical affairs and commercial insights into
outcomes to address modern market realities.
We bring together a talented team of professionals, who work
across more than 110 countries, with a deep understanding of
patient and physician behaviors and market dynamics. Together
we share insights, use the latest technologies and apply advanced
business practices to speed our customers’ delivery of important
therapies to patients.
Syneos Health supports a diverse, equitable and inclusive
culture that cares for colleagues, customers, patients, communities
and the environment.
To learn more about how we are Shortening the distance
from lab to life®, visit
syneoshealth.com.
Investor Relations Contact: |
Press/Media Contact: |
Ronnie Speight |
Gary Gatyas |
Senior Vice President, Investor Relations |
Executive Director, External Communications |
+1 919 745 2745 |
+1 908 763 3428 |
Investor.Relations@syneoshealth.com |
gary.gatyas@syneoshealth.com |
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jan 2025 to Feb 2025
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Feb 2024 to Feb 2025